companies / incyclixbio-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-22 json
| total_raised | 50,000,00050.0M | ○ |
|---|---|---|
| founded | 2022 | |
| hq | Durham | |
| industry | unknown | |
| stage | series-b+ |
Incyclix Bio develops cancer therapies that target the cell-cycle machinery, led by INX-315, a selective CDK2 inhibitor in clinical trials. It is aimed at patients with cancers driven by abnormal proliferation, including CDK4/6-resistant breast cancer and CCNE1-amplified tumors. It draws on its founders' long history in CDK inhibitor development.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-10-01 | series-b | 30,000,00030.0M | null | ○ |
Nginx, WordPress, Typekit, Adobe Fonts, Yoast SEO 27.1.1, Google Analytics, Google Tag Manager, Slick, jQuery Migrate 3.4.1, DoubleClick Floodlight, Contact Form 7 6.1.5, WP Engine
| fact | status | src |
|---|---|---|
| Series B, $30.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |